INTRODUCTION
More than 30 million people are infected with HIV.
1 Antiretroviral treatment (ART) dramatically decreases mortality 2 but is expensive and inconvenient, and HIV-infected people still have an increased risk of malignancies, 3 cardiovascular 4 and neurologic 5 disease, and shortened life expectancy. 6 Therefore, a cure for HIV remains an important treatment goal.
Adoptive T cell therapy as a strategy to treat or cure HIV has been investigated for decades. [7] [8] [9] [10] [11] Because residual HIV expression continues despite effective ART [12] [13] [14] [15] [16] and is required for viral rebound, HIV-infected cells should theoretically be targetable by a T cell therapeutic agent. Several mechanisms are thought to be responsible for the apparent failure of autologous cytotoxic T lymphocytes (CTLs) to clear reactivated cells in HIV-infected individuals: HIV evolution prior to ART quickly selects for CTL escape mutations; [17] [18] [19] HIV Nef mediates downregulation of major histocompatibility complex class I (MHC-I), 20, 21 protecting HIV-infected cells from T cell receptor (TCR)-dependent CTL killing; and HIV-specific CTL responses may be limited by exhaustion 22, 23 or peripheral immune tolerance. 24, 25 Over the last decade, major advances have been made in engineering human T cells via introduction of chimeric antigen receptors (CARs) to enable specific lysis of pathogenic targets. [26] [27] [28] [29] Because CAR T cell activity is MHC-independent, potent, and enforced by expression of an engineered gene cassette, anti-HIV CAR T cells might overcome the limitations of autologous CTLs. In fact, although the major clinical success has occurred in treatment of select lymphoid malignancies, one of the earliest CAR T cell therapies to reach clinical trials was designed for the treatment of HIV. 8 The early attempts at CAR T cell therapy for HIV involved the adoptive transfer of T cells expressing a fusion of the human CD4 extracellular domain (a ligand of HIV) to the CD3z signaling domain. 8 In a randomized trial, this first-generation CAR was safe and reduced the HIV reservoir as measured by a viral outgrowth assay, and CAR + cells were detectable for 10 years despite the lack of clinical benefit. [30] [31] [32] The efficacy of this approach was likely compromised because of limited CAR activity in the absence of an intracellular co-stimulatory signaling domain and the potential for HIV infection of T cells expressing the CD4 CAR. 10, 33 A panel of novel high-affinity, broadly neutralizing monoclonal antibodies (bNAbs) recognizing the HIV envelope glycoprotein have been isolated and characterized over the last decade. 34, 35 We predicted that single-chain variable fragments (scFvs) derived from these bNabs could be used to develop potent anti-HIV CARs (HIVCARs), and multiple scFvs could be selected to develop HIVCARs targeting different epitopes of the HIV envelope glycoprotein.
CCR5 is the primary co-receptor for HIV. 36, 37 Individuals with an allelic variant that is not functional (CCR5D32) are protected from CCR5-tropic HIV infection. 38 Hematopoietic stem cell transplant using a CCR5D32 donor led to the only known cure of HIV-1 infection, 39, 40 and T cells treated with engineered nucleases that introduce mutations at the CCR5 locus are resistant to HIV, [41] [42] [43] [44] [45] accelerating ongoing efforts to develop gene editing-and cell-based therapeutic agents for HIV. 11, 46 Using new gene-editing techniques, it has recently become possible to achieve high rates of homology-directed recombination (HDR) of therapeutic cassettes into targeted loci, including CCR5 in primary T cells. [47] [48] [49] [50] We have previously shown introduction of cDNA expression cassettes at the CCR5 locus in primary human T cells using an mRNA-delivered megaTAL nuclease and a homologous AAV donor template at rates of up to 60%. 48 HDR has the potential advantage of simultaneous introduction of a CAR and disruption of CCR5 to protect engineered cells from HIV. Based on these combined rationales, the current study tested the concept that T cells utilizing CARs based on scFvs derived from high-affinity bNAbs and containing second-generation co-stimulatory domains, in parallel with genetic protection from HIV by disruption of CCR5, would be effective at targeting HIV-infected cells. Additionally, we evaluated the functional activity of T cells and achieved CCR5 disruption by delivery of the HIVCAR gene cassette into CCR5 via HDR.
RESULTS

Construction of HIVCARs Derived from bNAbs Targeting Alternative Epitopes on the HIV Envelope Glycoprotein
HIV bNAbs are human antibodies isolated from HIV-infected donors that neutralize multiple HIV strains in vitro. 34, 35 Hundreds of monoclonal bNAbs of varying breadth and potency have been identified and characterized in neutralization assays. 51 We chose four highbreadth, high-potency bNAbs that bind different epitopes on the HIV envelope glycoprotein ( Figure 1A ): PGT-145 (variable regions 1 and 2 glycan loop), VRC07-523 (CD4-binding site), PGT-128 (mannose-rich region), and 10E8 (gp41 membrane-proximal external region). [51] [52] [53] [54] To generate anti-HIVCARs, the heavy and light chains of each bNAb were synthesized as an scFv and cloned into a lentivirus (LV) second-generation CAR expression construct; blue fluorescent protein (BFP) was co-expressed downstream of a self-cleaving peptide ( Figure 1B ). An anti-CD19 scFv CAR (CD19CAR) was used as a control.
Initial transduction of HIVCAR LVs at MOI $2 in primary human CD3 + cells produced 7%-20% positive cells ( Figure 1C ). Although much higher levels of T cell transduction were achievable with our LV constructs, a low MOI was utilized in our experiments to permit assessment of functional activity of each construct in cells with $1 viral integration/cell and, thus, limit variability that might be caused by variations in cell surface expression. The CD3 + cells used were obtained from three unique donors. T cells from each donor were transduced with all four HIVCAR LVs or the control CD19CAR LV in parallel to allow discrimination between donor T cell versus HIVCAR variations. T cells were sorted on BFP to enrich for transduced cells and match expression levels between HIVCAR T cell populations. Eight days after sort enrichment, expression was stable at 42%-58% BFP + ( Figure 1C ). Differences in HIVCAR expression by BFP mean fluorescence intensity (MFI) were not significant between the constructs at this time point ( Figure 1D ). To confirm that the scFvs were expressed at the cell surface, cells transduced with the VRC07-523-HIVCAR and CD19CARs, which have kappa light chains, were stained with Protein L, demonstrating a linear correlation of Protein L staining with BFP expression, as would be expected, because of their cis linkage via a 2A sequence ( Figure 1E ). T ratio, and all except 10E8 had significant decreases at a 3:1 ratio and above ( Figure 2E ). In a live virus assay, all HIVCARs except 10E8 were able to control viral replication of the HIV-1 JR-CSF strain, as measured by HIV capsid ELISA ( Figure S2) .
Of the scFv CARs tested, the PGT145-and VRC07-523-CARs appeared to show the most consistent potency in our initial assays. Interestingly, the VRC07-523-CAR targets a similar region of the HIV envelope as the early anti-HIV CD4-based CAR. 53 Given the tendency for HIV to mutate in response to pressures, it is likely to be advantageous to develop anti-HIV CARs targeting multiple epitopes on the HIV envelope. The PGT145-CAR, targeting the V1/V2 glycan region, was therefore selected for testing in conjunction with CCR5 disruption.
Homology-Directed Repair for Targeted Integration of PGT145-HIVCAR at the CCR5 Locus CD4 + T cells have an important role in maintaining the survival of cytotoxic lymphocytes in vivo, and recent studies with CAR T cells targeting lymphoma suggest that a defined mix of both CD4 + and CD8 + T cells may have higher efficacy and persistence in patients. 31, 56, 57 However, CD4 + CAR T cells are expected to be vulnerable to HIV-1 infection, and there is evidence that CD8 + CAR T cells expressing the CD4-based CAR can be infected. 10, 33 Because CCR5 is the predominant co-receptor used for HIV entry, we tested the effect of CCR5 disruption on HIVCAR T cell function. We have previously published the targeted integration of a CAR construct at the CCR5 locus with rates of 10%-15% in primary human T cells. 48 Using the CCR5 megaTAL and an AAV donor template similar to that described previously ( Figure 3A) , we introduced the PGT145-HIV-CAR at the CCR5 locus or the CD19CAR as a control. After sort enrichment for BFP + cells, the resultant CCR5-HIVCAR (PGT145) T cells were specifically activated, as measured by cell surface CD137 expression at 24 hr, when stimulated with the HIV-infected (HIV pos ) cell line ( Figures 3B and 3C ). CCR5-HIVCAR T cells also specifically killed HIV-infected cells in the presence of ART in a dose-dependent fashion, as measured by reduction in the ratio of HIV pos cells (GFP + ) to HIV neg cells (mCherry + ) and reduction in the percentage of HIV pos live target cells (Figures 3D-3F ).
CCR5-Edited HIVCAR T Cells More Effectively Suppress Viral Replication
The efficacy of adoptive HIV CAR T cell therapy is expected to be challenging in the context of active viral replication. To test whether CCR5 disruption provides a meaningful benefit in this context, HIVCAR and control CD19CAR T cells with or without CCR5 modification were added to cultures containing peripheral blood mononuclear cells (PBMCs) with actively replicating HIV. Control of HIV replication was monitored daily by ELISA for the HIV capsid protein p24 ( Figure 4A ). HIVCAR T cells produced by three methods were directly compared: LV delivery of the PGT145-HIVCAR, LV delivery of the PGT145-HIVCAR plus megaTAL disruption of CCR5 via non-homologous end joining (NHEJ), and HDR using the CCR5 megaTAL plus AAV donor template with CCR5 homology arms (CCR5-PGT145HIVCAR). Through days 1-3 of co-culture with infected PBMCs, all three HIVCAR T cell products controlled viral replication significantly better than CD19CAR T cells, and there were no significant differences between the three types of HIVCAR T cells. However, on days 4-5, there was a significant increase in viral particles when HIVCAR T cells without CCR5 disruption were used ( Figure 4B ). These findings support the idea that, in the presence of active virus replication, CCR5 disruption is likely to be beneficial and/or critical for effective HIVCAR T cell therapy.
DISCUSSION
Our studies lay an important foundation for further development of anti-HIV CAR adoptive cellular therapies. We demonstrate robust anti-HIV activity of four distinct second-generation CARs derived from bNAbs. Each CAR tested used an scFv targeting a distinct epitope on the gp120 glycoprotein, demonstrating that bNAbs of multiple classes are compatible with CAR technology. We also demonstrate that HIVCAR T cells exhibit activity toward HIV-infected cell lines in the presence of ART. Each of the bNAb-based HIV-CAR expression constructs tested induced specific T cell activation and killing of HIV-infected cells compared with control CD19CAR T cells, and no HIVCAR T cell activation occurred in culture with the uninfected cell line. These mixed target cell cultures grown in the presence of ART were designed to mimic the anticipated scenario encountered during clinical usage of HIVCAR T cells; clearance of HIV-infected cells in these assays demonstrates the potential of HIV CARs to target and eliminate HIV-infected cells in individuals on ART.
Among the candidate HIVCARs evaluated, the PGT145 and VRC07-523-HIVCARs appeared to be the most effective in our studies, exhibiting efficient CD137 upregulation and cytokine production, killing at low effector to target ratios, and sustained efficacy in the setting of CCR5 disruption (for PGT145). PGT128 CAR T cells, in contrast, exhibited lower rates of CD137 expression after co-culture with HIV pos targets and appeared to clear HIV pos cells less well than other HIV-CAR T cells but produced cytokines after stimulation with cells expressing an alternative HIV envelope. Ali et al. 58 recently compared the potency of bNAb-based HIV CARs against HIV-1 NL4-3 -infected T2 cells and found the CAR based on the PGT128 bNAb to be the www.moleculartherapy.org least effective, whereas that based on the 10E8 bNAb was the most potent. Here we observed that 10E8 HIVCAR T cells exhibited an activation profile that varied between donors and killed less potently than PGT145-and VRC07-523-HIVCAR T cells in our target cell assays. The 10E8 antibody binds at the membrane-proximal external region (MPER), which may be less accessible than other regions of the HIV envelope. In a live-virus assay, the 10E8 HIVCAR T cells were also the only HIVCAR cells tested that failed to control HIV JR-CSF replication, as measured by supernatant p24. Although 10E8 has been shown to neutralize JR-CSF efficiently, 52 our finding is perhaps not surprising given the observation that anti-MPER antibodies bind poorly to the surface of infected cells. 59 The potency of different HIVCARs against different viral variants supports the pursuit of HIVCAR combinations. Our experiments were designed to test the feasibility of using bNAbs to generate multiple CARs for a potentially combinatorial approach for HIV therapy in the clinic rather than to specifically HIVCAR T cells at each E:T ratio. Shown are mean ± SEM for n = 5 (C) of three (E and F) unique experiments using CAR T cells generated from three independent human donors. p values calculated using unpaired two-tailed t test are indicated as follows: *p < 0.05, **p < 0.001.
compare the effectiveness of targeting a particular region of the HIV envelope. Additionally, even with the most studied CD19CAR, it is not yet clear which in vitro assays best predict clinical success. 26 Therefore, we hesitate to make definitive claims regarding the relative performance of candidate HIVCARs derived from the alternative bNAb scFvs. Given the propensity of HIV to mutate to evade specific pressures, it seems prudent to develop multiple HIVCARs that target different epitopes and could be used in combination to treat HIV.
An important additional advance in this study is the use of gene editing to generate HIV-resistant HIVCAR T cells. CD8 + CAR T cells expressing a CD4-based CAR have previously been shown to be susceptible to HIV infection, 33 and it is likely that CD4 + T cells expressing this construct might be even more susceptible to infection. It is conceivable that this was a key limitation of the HIVCAR T cells studied in previous randomized trials. 30, 31 We show that it is possible to protect HIVCAR T cells by independent disruption of CCR5 by NHEJ or HDR. Both methods produce functional CAR T cells that kill HIV-infected cells in the presence of ART, and both types of HIV-resistant CAR T cells outperformed HIVCAR T cells without CCR5 disruption in live viral assays. Either gene-editing method could be used to generate further preclinical data. Ex vivo gene editing of CCR5 by NHEJ has been shown to be safe and effective in a phase I clinical trial, 44 whereas HDR is a newer technology that has not yet been tested clinically. However, HDR has a potential advantage in that it limits the number of possible integration events and may reduce the risk of insertional mutagenesis. In addition, because of the nature of the simultaneous CAR insertion/CCR5 disruption, enriching for CAR + cells generated through HDR also enriches for cells with CCR5 disruption. Finally, compared with LV delivery of the CAR, HDR has the added advantage that it can be done in the presence of ART, which may be an important safety feature during ex vivo manipulation of cells from HIV-infected individuals. Interestingly, we observed a trend for increased killing efficiency of HIV pos target cells in experiments using CCR5-PGT145-HIVCAR compared with LV-delivered PGT145-HIVCAR, particularly at lower effector-totarget cell ratios (Figures 2E and 3F ). It will be important to directly compare these cell products in additional in vivo and in vitro assays to determine whether this observation has functional relevance.
Although our in vitro data on CCR5-disrupted HIVCAR T cells highlight the promise of a CAR T cell approach to eradication of HIV, several potential in vivo challenges exist. One concern is the potential to induce a cytokine release syndrome (CRS). CRS and associated neurological toxicities are seen in 10%-20% of patients treated with CD19CAR T cells, and studies of these patients suggest that cell dose, conditioning regimen, CAR T cell composition, and, particularly, tumor burden influence the risk of CRS. 60, 61 The number of HIV-infected target cells in patients on ART is dramatically less than target cell numbers in individuals with leukemia. Consequently, the risk for HIVCAR-induced CRS would be predicted to be lower.
A significant challenge regarding the efficacy of HIVCAR T cell therapy is the requirement for persistent activity. Mathematical modeling suggests that a 5-year HIV-free period may be necessary to establish an effective cure. 62 The CAR T cell dose, composition, phenotype, and immune-conditioning regimens will all likely influence CAR T cell persistence. Another potential concern is that HIV-CAR constructs might be immunogenic. Although CAR constructs are assembled from human protein domains, the junctions between these domains may be seen as foreign, and, therefore, may require additional optimization. Persistent activity also requires preventing HIV Env escape. In the absence of ART, HIV has an extremely high mutation rate, allowing rapid selection for resistance mutations, which would likely include resistance to a single scFv-based CAR. We envision addressing this concern by adoptive transfer of anti-HIV CAR T cells to individuals who are initially on ART and by combining CAR T cells targeting distinct epitopes on HIV Env, potentially in concert with agents that promote viral activation in latently infected cells. 63 In summary, we have demonstrated the feasibility and utility of a novel strategy for HIVCAR therapy that not only targets HIV-infected cells in the presence of ART but also protects the effector cells from HIV infection. This approach leverages recent advances in the ability to identify potent bNAbs, CAR technology, and the field of gene therapy, including the ability to perform high-efficiency gene editing of primary cells, and warrants further preclinical testing in animal models. 
MATERIALS AND METHODS
CAR Design and Vector Cloning
A plasmid with a T7 promoter driving the CCR5 megaTAL coding sequence and pRRL-MND-CD19CAR-BFP have been described previously. 48 HIV scFvs were exchanged with that of the CD19 scFv in this plasmid as follows. scFvs from the previously reported human anti-HIV bNAbs PGT145, PGT128, 10E8, and VRC07-523 [51] [52] [53] were gene-synthesized by GenScript ( Figure S3 ). Synthesized scFvs included additional sequences for cloning into BamHI and NheI sites of pRRL-MND-CD19CAR-BFP while maintaining the reading frame with upstream human CD8 signal peptide and downstream CAR domains (including CD8a hinge and transmembrane domains and 4-1BB and CD3z intracellular signaling domains 64 ). The AAV6-CCR5-HIVCAR plasmid is as described previously, 48 except that RQR8 was replaced by BFP. Constructs were verified by restriction digestion and sequencing. For LVs used to transduce target cell lines, either an mCherry or GFP fluorophore was cloned between an MND promoter 65 and a woodchuck hepatitis virus post-transcriptional response element (WPRE) in the pRRL backbone. Viral LV (vesicular stomatitis virus G protein [VSV-G] pseudotyped) and AAV6 were produced, and titers were determined as described previously. C (except where noted) with 5% CO 2 . Cells were maintained at a density of $1 Â 10 6 cells/mL by expansion into larger culture volumes every 2-3 days. Primary T cell cultures were supplemented with the following recombinant human cytokines from PeproTech: interleukin-2 (IL-2, 50 ng/mL), IL-7 (5 ng/mL), and IL-15 (5 ng/mL). Primary PBMC cultures were supplemented with IL-2 (50 ng/mL, PBMC medium).
Generation of CAR-Modified T Cells by Lentiviral Gene Transfer or Gene Editing
For gene transfer using LVs, 1Â 10 6 primary human T cells were plated at 2 Â 10 6 /mL in the presence of 4 mg/mL Polybrene (Sigma-Aldrich) and 10 mL ($2 MOI) of LV. Cells were incubated overnight, and then an additional 1 mL medium was added. For gene editing, CAR expression cassettes were targeted to the CCR5 locus using a CCR5 megaTAL nuclease followed by AAV6-CCR5.CAR.BFP as described previously. 48 Briefly, T cells (1 Â 10 6 /mL) were stimulated at a 1:1 ratio with CD3/CD28 beads (Dynal Beads, Thermo Fisher Scientific) for 48 hr, washed, and incubated at 5 Â 10 5 /mL without beads for 16 hr. 2.5-3 Â 10 5 cells were then transfected with 1 mg CCR5 mega-TAL mRNA (generated as described previously) 48 using the Neon Transfection System and a 10 mL tip at the following settings: 1,400 V, 10 ms, 3 pulses. Electroporated cells were immediately transferred to 200 mL pre-warmed T cell medium in a 96-well plate and incubated at 30 C for 22-24 hr, followed by standard culture conditions at PBMCs were cultured for 72 hr in PBMC medium with 2 mg/mL phytohemagglutinin (PHA, Sigma-Aldrich). The medium was then removed, and cells were re-plated at 5 Â 10 6 /mL in 6 mL PBMC medium, and HIV-1 JR-CSF was added to the PBMC culture at an MOI of 1 Â 10 À3 . After 2-hr incubation, the medium was removed, and the infected PBMCs were then incubated in fresh PBMC medium at 1 Â 10 6 /mL for an additional 72 hr. After 72 hr, infected PBMCs were diluted to 5 Â 10 5 cells/mL in T cell medium with cytokines. $2.5 Â 10 4 infected PBMCs (50 mL) were co-cultured with $5 Â 10 4 CAR T cells (100 mL) per well in a 96-well plate. 30 mL supernatant was removed from wells and frozen 1 hr after plating and then every 24 hr for the next 3 days; this volume was replaced with an equivalent volume of fresh T cell medium with cytokines. Viral antigen p24 concentrations were then quantified in supernatant fractions by p24 ELISA (Zeptometrix). Each condition was run in duplicate reactions, and each reaction was assayed in duplicate ELISAs.
Data Analysis
Flow cytometry data were analyzed using FlowJo software version 9.2 or 10.7 (Tree Star). Statistical analyses were performed using GraphPad Prism 6 (GraphPad). Tests of statistical significance were performed using unpaired two-tailed Student's t test or ANOVA.
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